Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

<p>SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) &#8212; Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that interim clinical safety and biodistribution data will be presented at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, which will be held from October 24-27, [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/excision-biotherapeutics-announces-presentation-of-interim-clinical-data-for-ebt-101-in-latent-hiv-at-upcoming-european-society-of-gene-and-cell-therapy-esgct-2023-annual-congress/">Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>